TC BIOPHARM, the Scottish immunotherapy company, has secured more than £6.25 million of investment to fund the latest stage of its pioneering cancer treatment.
In a major vote of confidence for the Scottish life sciences sector, TCB has attracted funding from Japan’s Nipro Corporation and the Scottish Investment Bank (SIB) to bankroll phase three of trials of its lead ImmuniCell product. Funding has also been secured from family sources.
TCB co-founder and chief executive Dr Michael Leek declared attracting Series A funding is a “really a big deal” for the company. He highlighted the scale of the deal and the importance of the backing from the Nipro Corporation, which led the investment round. Until now the funding secured by the firm to date in the Series C category, with investments made typically in the £1m to £2m range… Read full article >>
Investing Women are proud to have backed TC Biopharm from the outset.